Methods of producing and isolating .sup.68Ga, .sup.89Zr, .sup.64Cu, .sup.63Zn, .sup.86Y, .sup.61Cu, .sup.99mTc, .sup.45Ti, .sup.13N, .sup.52Mn, or .sup.44Sc and solution targets for use in the methods are disclosed. The methods of producing .sup.68Ga, .sup.89Zr, .sup.64Cu, .sup.63Zn, .sup.86Y, .sup.61Cu, .sup.99mTc, .sup.45Ti, .sup.13N, .sup.52Mn, or .sup.44Sc include irradiating a closed target system with a proton beam. The closed target system can include a solution target. The methods of producing isolated .sup.68Ga, .sup.89Zr, .sup.64Cu, .sup.63Zn, .sup.86Y, .sup.61CU, .sup.99mTC, .sup.45-Ti, .sup.52Mn, or .sup.44Sc by ion exchange chromatography. An example solution target includes a target body including a target cavity for receiving the target material; a housing defining a passageway for directing a particle beam at the target cavity; a target window for covering an opening of the target cavity; and a coolant gas flow path disposed in the passageway upstream of the target window.

The present invention provides a method for producing molybdenum-99 comprising: i) providing an electron accelerator; ii) providing a molybdenum converter/target unit (Mo-CTU) comprising one or more metallic components, wherein each one of said metallic components is made of a material selected from the group consisting of natural molybdenum, molybdenum-100, molybdenum-98, and mixtures thereof; iii) directing an electron beam generated via said electron accelerator onto said Mo-CTU to produce a braking radiation (bremsstrahlung); iv) employing said bremsstrahlung onto said Mo-CTU to produce molybdenum-99 and neutrons via a photo-neutron reaction; v) slowing down the neutrons produced in step iv) with a low atomic liquid, e.g. distilled water; and optionally vi) employing the neutrons produced in step iv) to produce a complementary amount of molybdenum-99 via a neutron capture reaction on said Mo-CTU. The invention further provides an apparatus for producing molybdenum-99.

The present invention relates to a column chromatographic method of manufacturing non-carrier-added high-purity .sup.177Lu compounds for medicinal purposes. In the method in accordance with the invention a cation exchanger and a suitable chelating agent are used. With the method in accordance with the invention it is possible for the first time to provide non-carrier-added high-purity .sup.177Lu compounds in milligram amounts for pharmaceutical-medicinal purposes from .sup.176Yb compounds irradiated with thermal neutrons, the radionuclides .sup.177Lu and .sup.176Yb being present in an approximate mass ratio of 1:10.sup.2 to 1:10.sup.10 for purification.

A system for producing technetium-99m from molybdate-100. The system comprises: a target capsule apparatus for housing a Mo-100-coated target plate; a target capsule pickup apparatus for engaging and delivering the target cell apparatus into a target station apparatus; a target station apparatus for receiving and mounting therein the target capsule apparatus. The target station apparatus is engaged with a cyclotron for irradiating the Mo-100-coated target plate with protons. The irradiated target capsule apparatus is transferred to a receiving cell apparatus comprising a dissolution/purification module for receiving therein a proton-irradiated Mo-100-coated target plate. A conveyance conduit infrastructure interconnects: (i) the target capsule pickup apparatus with the target station apparatus, (ii) the target station apparatus and the receiving cell apparatus; and (iii) the receiving cell apparatus and the dissolution/purification module.

An equatorial anthropic radiation source and a method of making an equatorial anthropic radiation source are described. The radiation source is useful in diagnostic imaging applications in healthcare or other industries (e.g. computerized three-dimensional segmental imaging; Crompton scattering imaging techniques; radiation detector check and calibration, in particular CdZnTe detectors commonly used in medical imaging).

A method includes sterilizing a column assembly including a column having a parent radionuclide contained therein with a sterilizer. The method further includes transferring the column assembly from the sterilizer to a first clean room environment, transferring the column assembly from the first clean room environment to a second clean room environment, and collecting a sterility test sample from the column assembly within the second clean room environment.

The present disclosure relates to systems and methods for producing tailored solutions or medicaments containing radioactive isotopes (e.g., alpha particle emitting radioactive isotopes). The solutions may be produced by appropriate aging and separation steps. Therapeutically effective amounts of Ac-225 and/or Bi-213 may thus be obtained.

An initial introduction control part introduces an aqueous solution containing molybdenum 99 and technetium 99m, and an organic solvent being capable of dissolving the technetium 99m into an extraction tank. A micro-mixing control part micro-mixes the aqueous solution and the organic solvent by heating and stirring a mixed solution of the aqueous solution and the organic solvent introduced into the extraction tank with a heater, while applying ultrasonic to the mixed solution. A separation control part separates the mixed solution micro-mixed into two phases of aqueous solution and an organic solvent. A taking-out introduction control part passes the organic solvent separated into two phases through an adsorption column be capable of adsorbing molybdenum 99 and introduces the organic solvent into an evaporation elution tank. An evaporation control part evaporates the organic solvent and leaves residue by reducing pressure inside the evaporation elution tank and heating the organic solvent introduced into the evaporation elution tank with a heater, while applying ultrasonic to the organic solvent. An elution control part introduces physiological saline solution into the residue and elutes technetium 99m into the physiological saline solution from the residue.

The present disclosure relates processes and systems for producing and/or purifying .sup.68Ga from an irradiated substrate of .sup.68Zn. In some embodiments, the process rely on the use two cation-exchange chromatography columns to separate .sup.68Ga from .sup.68Zn and other radionuclides and metallic impurities. The process achieves a high overall yield of .sup.68Ga and a high effective molar activity while being implementable in a time compatible with the short half-life of .sup.68Ga. In additional embodiments, the process is implemented by an automated system.

The invention provides an automated method for isolating a targeted isotope, the method having the steps of supplying a dissolved uranium targets into a first reaction environment; precipitating non-targeted isotope within the first reaction environment transferring liquid phase targeted isotope to a second reaction environment; precipitating the liquid phase targeted isotope in the second reaction environment; dissolving the precipitated targeted isotope; transferring the dissolved targeted isotope to a third reaction environment; and precipitating non-targeted isotope (i.e., iodine), such that the targeted isotope remains in the solution. Also provided is an automated system for isolating isotopes, the system having a plurality of reaction environments adapted to pneumatically receive and disgorge reactants and products via remotely actuated valves positioned between each of the reaction environments.